相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission
Mazyar Shadman et al.
BLOOD (2022)
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
M. R. Bishop et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
F. L. Locke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Alexander Spira et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma
Mehdi Hamadani et al.
BLOOD (2021)
Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients ( Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study
Manali Kamdar et al.
BLOOD (2021)
Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?
Nirav N. Shah et al.
BLOOD (2021)
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
Paolo F. Caimi et al.
LANCET ONCOLOGY (2021)
ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Brad S. Kahl et al.
Clinical Lymphoma Myeloma & Leukemia (2021)
ESTIMATION OF LONG‐TERM SURVIVAL WITH TAFASITAMAB + LENALIDOMIDE (LEN) IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL)
G Salles et al.
HEMATOLOGICAL ONCOLOGY (2021)
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Laurie H. Sehn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
Nagesh Kalakonda et al.
Lancet Haematology (2020)
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
Gilles Salles et al.
LANCET ONCOLOGY (2020)
Point mutation inCD19facilitates immune escape of B cell lymphoma from CAR-T cell therapy
Zhen Zhang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
TO THE EDITOR: CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy COMMENT
Bicky Thapa et al.
BLOOD ADVANCES (2020)
A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Brad S. Kahl et al.
CLINICAL CANCER RESEARCH (2019)
ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies
Francesca Zammarchi et al.
BLOOD (2018)
Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine
John A. Hartley et al.
SCIENTIFIC REPORTS (2018)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump et al.
BLOOD (2017)
Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload
Arnaud C. Tiberghien et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson et al.
NATURE MEDICINE (2015)
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
Laura R. Saunders et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation
Mehdi Hamadani et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy
Matthew J. Maurer et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12
Michael Crump et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma
Vadim Ivanov et al.
LEUKEMIA & LYMPHOMA (2014)
SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
May S. Kung Sutherland et al.
BLOOD (2013)
Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial
Nicolas Mounier et al.
HAEMATOLOGICA (2013)
The development of pyrrolobenzodiazepines as antitumour agents
John A. Hartley
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
分享论文
